Pathways Study: Puberty Suppression

Joe Robertson Excerpts

Monday 22nd June 2026 Commons Chamber

[James Murray]

The number of expected participants in the trial is 226. That is not a firm target—it does not have to be exactly that number—but that is the number at which statistically significant conclusions can be drawn. The 226 will fall into two camps: one will access the medical treatment immediately and the other will access it after one year. In that way, we will have clinical evidence from which we can draw conclusions and on which we can base future decisions. The number has been chosen so that the evidence can be relied on in the future to take decisions about whether, and if so how, to continue the use of these treatments.

[Joe Robertson (Isle of Wight East) (Con)]

A parent cannot consent to their child engaging in sexual activity and soon they will not be able to consent to their child having a social media account, so why does the Secretary of State think that a parent should consent to drugs being administered to their child to supress their puberty and alter their sexual development?

[James Murray]

We are following clinical advice. We are ensuring that there is a triple lock on the consent for children and young people to be involved in this trial, involving the consent or assent of the young person themselves, parents or guardians, and the NHS care team—the national multidisciplinary team that I mentioned earlier. That is how this trial ensures that there is a high bar for being involved in it and that all aspects of a young person’s life are considered before they are approved.